Preclinical Toxicological Evaluation of IDM01: The Botanical Composition of 4‑Hydroxyisoleucine‑ and Trigonelline‑based Standardized Fenugreek Seed Extract

Objective: To evaluate acute oral toxicity (AOT), subchronic (90‑day repeated dose) toxicity, mutagenicity, and genotoxicity potential of IDM01, the botanical composition of 4‑hydroxyisoleucine‑ and trigonelline‑based standardized fenugreek (Trigonella foenum‑graecum L) seed extract in laboratory rats. Materials and Methods: The AOT and subchronic (90‑day repeated dose) toxicity were evaluated using Sprague‑Dawley rats as per the Organisation for Economic Co‑operation and Development (OECD) guidelines No. 423 and No. 408, respectively. During the subchronic study, the effects on body weight, food and water consumption, organ weights with hematology, clinical biochemistry, and histology were studied. The mutagenicity and genotoxicity of IDM01 were evaluated by reverse mutation assay (Ames test, OECD guideline No. 471) and chromosome aberration test (OECD guideline No. 473), respectively. Results: The IDM01 did not show mortality or treatment‑related adverse signs during acute (limit dose of 2000 mg/kg) and subchronic (90‑day repeated dose of 250, 500, and 1000 mg/kg with 28 days of recovery period) administration. The IDM01 showed oral median lethal dose (LD50) >2000 mg/kg during AOT study. The no‑observed adverse effect level (NOAEL) of IDM01 was 500 mg/kg. IDM01 did not show mutagenicity up to a concentration of 5000 μg/plate during Ames test and did not induce structural chromosomal aberrations up to 50 mg/culture. Conclusions: IDM01 was found safe during preclinical acute and subchronic (90‑day repeated dose) toxicity in rats without mutagenicity or genotoxicity.